Published in Cell · View the paper (DOI)
Researchers at Karolinska Institutet and UBC found that a genetically modified variant of ACE2 reduced SARS-CoV-2 viral growth by a factor of 1,000 to 5,000 in cell cultures. The study suggests the potential for a novel drug treatment to help patients with early-stage COVID-19.
Coverage from 2 institutions